LTBR antibody (Cysteine-Rich Domain)

Catalog No. ABIN1169122

This Rat Monoclonal antibody specifically detects LTBR in Func. It exhibits reactivity toward Mouse. It has been mentioned in 3+ publications

Quick Overview for LTBR antibody (Cysteine-Rich Domain) (ABIN1169122)

Target: LTBR (Lymphotoxin beta Receptor (TNFR Superfamily, Member 3) (LTBR))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This LTBR antibody is un-conjugated

Application: Functional Studies (Func)

Clone: 3C8

Product Details anti-LTBR Antibody

Binding Specificity: AA 31-221, Cysteine-Rich Domain

Specificity: Recognizes mouse LTbetaR.

Cross-Reactivity: Mouse (Murine)

Purification: Purified from concentrated hybridoma tissue culture supernatant.

Purity: >95 % (SDS-PAGE)

Immunogen: Recombinant mouse LTbetaR (cysteine-rich region) (aa 31-221).

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

The monoclonal antibody to mouse LTbetaR is an agonist that can be used for the investigation of the regulation of BAFF (BlyS), chemokines and integrins using in vivo and tissue culture models, the development of NK cells and NK T cells, to study the regulation of NF-kappaB family of transcription factors in regulation of inflammation and homeostasis, particularly RelB NF-kappaB2 pathway. For use as an agonist the MAb to LTbetaR is added to cell cultures at 2μg/ml. For in vivo use, mice are injected intraperitoneally with 50μg of agonistic MAb to LTbetaR in sterile phosphate saline buffer.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: In PBS containing 10 % glycerol and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Expiry Date: 12 months

References for anti-LTBR antibody (ABIN1169122)

Vondenhoff, Greuter, Goverse, Elewaut, Dewint, Ware, Hoorweg, Kraal, Mebius: "LTbetaR signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 9, pp. 5439-45, (2009) (PubMed).

Benedict, De Trez, Schneider, Ha, Patterson, Ware: "Specific remodeling of splenic architecture by cytomegalovirus." in: PLoS pathogens, Vol. 2, Issue 3, pp. e16, (2006) (PubMed).

Banks, Rickert, Benedict, Ma, Ko, Meier, Ha, Schneider, Granger, Turovskaya, Elewaut, Otero, French, Henry, Hamilton, Scheu, Pfeffer, Ware: "A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 174, Issue 11, pp. 7217-25, (2005) (PubMed).

Target Details for LTBR

Target: LTBR (Lymphotoxin beta Receptor (TNFR Superfamily, Member 3) (LTBR))

Alternative Name: LTbetaR

Background: The LTbetaR activates two different NF-kappaB pathways that lead to distinct patterns of gene induction, including selected chemokines and the cytokine BAFF, which is essential for the survival of mature B lymphocytes. LTbetaR activates the classical NF-kappaB (relA/p50) pathway, like the type 1 TNF receptor (TNFR1), that regulates proinflammatory genes, like the chemokine MIP1beta. However, LTbetaR, unlike TNFR1, also activates the processing of p100 to form RelB/p52 complexes, which activate genes involved in lymphoid organ formation and lymphocyte survival.

UniProt: P50284

Pathways: NF-kappaB Signaling